Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Non-Current Liabilities (2020 - 2025)

UroGen Pharma (URGN) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 2.95% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Dec 2025, up 2.95%, and an annual FY2025 reading of $3.9 million, up 2.95% over the prior year.
  • Other Non-Current Liabilities was $3.9 million for Q4 2025 at UroGen Pharma, up from $3.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $3.9 million in Q4 2025 and bottomed at $2.7 million in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $3.2 million, with a median of $3.0 million recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities grew 18.69% in 2024, then grew 2.95% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $2.8 million in 2021, then increased by 6.19% to $3.0 million in 2022, then grew by 5.83% to $3.2 million in 2023, then increased by 18.69% to $3.8 million in 2024, then grew by 2.95% to $3.9 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for URGN at $3.9 million in Q4 2025, $3.8 million in Q3 2025, and $3.8 million in Q2 2025.